TOP > 外国特許検索 > METHOD FOR PROVIDING INFORMATION FOR EVALUATING PROGNOSIS OF LUNG CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF LUNG CANCER PATIENT, INTERNAL STANDARD, ANTIBODY, DEVICE FOR PREDICTING PROGNOSIS OF LUNG CANCER PATIENT, PROGRAM FOR PROGNOSIS PREDICTION DEVICE, AND RECORDING MEDIUM

METHOD FOR PROVIDING INFORMATION FOR EVALUATING PROGNOSIS OF LUNG CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF LUNG CANCER PATIENT, INTERNAL STANDARD, ANTIBODY, DEVICE FOR PREDICTING PROGNOSIS OF LUNG CANCER PATIENT, PROGRAM FOR PROGNOSIS PREDICTION DEVICE, AND RECORDING MEDIUM

外国特許コード F160008853
整理番号 (S2015-0084-N0)
掲載日 2016年9月23日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP052072
国際公開番号 WO 2016121715
国際出願日 平成28年1月26日(2016.1.26)
国際公開日 平成28年8月4日(2016.8.4)
優先権データ
  • 特願2015-012728 (2015.1.26) JP
発明の名称 (英語) METHOD FOR PROVIDING INFORMATION FOR EVALUATING PROGNOSIS OF LUNG CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF LUNG CANCER PATIENT, INTERNAL STANDARD, ANTIBODY, DEVICE FOR PREDICTING PROGNOSIS OF LUNG CANCER PATIENT, PROGRAM FOR PROGNOSIS PREDICTION DEVICE, AND RECORDING MEDIUM
発明の概要(英語) Provided is a method for predicting the possibility of the relapse of lung cancer even at an early stage, regardless of the types of the lung cancer. The possibility of the relapse of lung cancer can be predicted even at an early stage regardless of the types of the lung cancer by a method for providing information for predicting the prognosis of a lung cancer patient, wherein the method comprises determining the expressed amounts of at least four kinds of proteins, i.e., g1027 (Accession No. sp|P12814|ACTN1_HUMAN), g1237 (Accession No. sp|P22392-2|NDKB_HUMAN), g1463 (Accession No. sp|P35221|CTNA1_HUMAN) and g1821 (Accession No. sp|P51690|ARSE_HUMAN), in a sample from the lung cancer patient.
従来技術、競合技術の概要(英語) BACKGROUND ART
In most industrialized countries including Japan, in each portion of cancer deaths, deaths from lung occupies the second position 1. For lung cancer, early detection of improved and various treatments for improvement of the inspection method are performed, each year approximately 70,000 human lung odor Japan (hereinafter, simply referred to as a 'patient' is be described.) These die.
Causes the death of the major post-operative patients relapse in metastasis. Therefore, in Japan, the time of surgery on image diagnosis which cannot be visually found that in order to suppress the metastasis of cancer cells, tegafur after surgery, uracil (UFT (registered trademark) ) having a relatively small side effects such as anti-cancer agent to 2 years post-operative treatment is performed to continue to drink. By the post-surgical treatment, only the observation is performed after the surgery than the method of treatment, relapse of the patient can be suppressed. However, statistically, about 7 of the patient to heal by the interrupt is said to be a surgical procedure. Therefore, the rate of the patient is about 7, although the anti-cancer agent is not required and in the post - treatment, as well as damage to the body, being a heavy burden economically.
On the other hand, the remaining approximately 3 for the interrupt, the cancer cells is not completely removed in the surgery, is called as a recurrence. The rate of the patient such that this approximately 3, after surgery, the anti-cancer agent is a stronger than the UFT treatment is preferably performed. However, postoperative UFT uniformly in the present state of the anti-cancer agent such as in the administration. Therefore, the likelihood of recurrence of each of the patients post-surgery check the presence of, most suitable for the patient post-operative treatment is preferably performed.
In addition, in Europe, in the case of the phase I light relatively symptoms of 'follow' is mostly used. However, I phase of progressive in the patient is also included in the patient. Therefore, advanced by the patient, such as surgery or an anti-cancer agent administered to the appropriate treatment to early but it is preferable that, at present, and the follow up is performed uniformly.
A method of predicting prognosis of the patient as the end of the operation, a lung adenocarcinoma in a sample collected from the living-body derived, myosin IIA and/or measuring the amount of vimentin expression, a method for predicting a prognosis (see Patent Document 1) are known.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
  • 発明者(英語)
  • TAKAHASHI TAKASHI
  • YANAGISAWA KIYOSHI
  • HIRAKAWA AKIHIRO
  • NAKATOCHI MASAHIRO
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
名古屋大学の公開特許情報を掲載しています。ご関心のある案件がございましたら、下記まで電子メールでご連絡ください。

PAGE TOP

close
close
close
close
close
close